Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1955 2
1957 1
1958 2
1960 1
1961 1
1962 2
1963 1
1964 1
1965 1
1966 1
1967 2
1968 1
1969 1
1970 2
1971 1
1973 2
1974 1
1976 4
1977 2
1979 3
1980 4
1981 4
1982 3
1983 2
1984 1
1985 2
1986 3
1990 3
1991 4
1992 2
1993 2
1994 2
1995 1
1996 2
1997 5
1998 5
1999 3
2000 3
2001 1
2002 3
2004 2
2005 4
2006 3
2007 3
2008 10
2009 10
2010 7
2011 4
2012 8
2013 9
2014 6
2015 8
2016 6
2017 7
2018 12
2019 18
2020 13
2021 18
2022 35
2023 35
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, Shameem SH, Chauhan T, Torrisi J, Ford J, O'Connor MN, Geuijen CAW, Schackmann RCJ, Lammerts van Bueren JJ, Wasserman E, de Stanchina E, O'Reilly EM, Ladanyi M, Drilon A, Somwar R. Schram AM, et al. Among authors: lui ajw. Cancer Discov. 2022 May 2;12(5):1233-1247. doi: 10.1158/2159-8290.CD-21-1119. Cancer Discov. 2022. PMID: 35135829 Free PMC article.
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, Crawford J, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M; AEGEAN Investigators. Heymach JV, et al. N Engl J Med. 2023 Nov 2;389(18):1672-1684. doi: 10.1056/NEJMoa2304875. Epub 2023 Oct 23. N Engl J Med. 2023. PMID: 37870974 Clinical Trial.
Tricin Biosynthesis and Bioengineering.
Lam PY, Lui ACW, Wang L, Liu H, Umezawa T, Tobimatsu Y, Lo C. Lam PY, et al. Among authors: lui acw. Front Plant Sci. 2021 Aug 26;12:733198. doi: 10.3389/fpls.2021.733198. eCollection 2021. Front Plant Sci. 2021. PMID: 34512707 Free PMC article. Review.
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. Miyazaki I, et al. Among authors: lui ajw. Nat Cancer. 2023 Sep;4(9):1345-1361. doi: 10.1038/s43018-023-00630-y. Epub 2023 Sep 21. Nat Cancer. 2023. PMID: 37743366 Free PMC article.
294 results